This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jay Shreiner Joins NxStage Board Of Directors

LAWRENCE, Mass., June 21, 2013 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jay W. Shreiner has been appointed to its Board of Directors effective immediately.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

Most recently, Mr. Shreiner served as Interim Chief Financial Officer for Behavioral Centers of America from April 2012 until its acquisition by Acadia Healthcare in December 2012. From 2006 to 2011, Mr. Shreiner was the Executive Vice President and Chief Financial Officer at RehabCare Group, Inc., a NYSE publicly traded healthcare services company that was acquired by Kindred Healthcare in 2011.  His career experiences include Ernst & Young, the B.F. Goodrich Company and 16 years at the Kellogg Company where he served on the Company's Global Strategic Leadership Team. Mr. Shreiner was also Chief Financial Officer for several private companies within Austin Ventures' portfolio of companies. 

"We are thrilled to have someone with Jay's broad experience join our board.  Jay's operational and financial expertise within healthcare services will be highly relevant as we work to accelerate adoption of our life changing therapy," stated Jeffrey Burbank, Chief Executive Officer, NxStage Medical, Inc.

"I'm looking forward to working with Jeff and NxStage's management team to help achieve the next level of growth," stated Mr. Shreiner.

Mr. Shreiner is a member of the Board of Directors of Global Partnership for Afghanistan. Mr. Shreiner received a B.B.A. in Accounting from Kent State University and an M.B.A in Banking & Finance from the Weatherhead School of Management at Case Western Reserve University.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq:NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2013. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Kristen Sheppard, ksheppard@nxstage.com 

 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,040.37 +29.69 0.16%
S&P 500 2,111.73 +4.34 0.21%
NASDAQ 5,082.9290 +12.9030 0.25%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs